{"id":"pegintron-plus-ribavirin","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Neutropenia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression / mood changes"},{"rate":"20-30","effect":"Headache"},{"rate":"20-30","effect":"Nausea"},{"rate":"10-15","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PEGIntron is a pegylated form of interferon alfa-2b that binds to interferon-alpha receptors on infected hepatocytes, triggering antiviral immune responses and inhibiting HCV replication. Ribavirin is a nucleoside analog that interferes with viral RNA synthesis and may enhance immune responses. The combination has synergistic antiviral activity against hepatitis C virus.","oneSentence":"PEGIntron (peginterferon alfa-2b) activates interferon signaling to suppress hepatitis C virus replication, while ribavirin inhibits viral RNA synthesis through multiple mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:58.545Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotype-dependent)"}]},"trialDetails":[{"nctId":"NCT01466192","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":108},{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT00780910","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":109},{"nctId":"NCT00780416","phase":"PHASE3","title":"Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-11","conditions":"Hepatitis C","enrollment":189},{"nctId":"NCT00781274","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-12","conditions":"Hepatitis C","enrollment":32},{"nctId":"NCT01468584","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-11","conditions":"Chronic Hepatitis C","enrollment":10},{"nctId":"NCT01718301","phase":"PHASE3","title":"HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin","status":"TERMINATED","sponsor":"Anna Cruceta","startDate":"2013-03-10","conditions":"Hepatitis C, HIV Infections, COINFECTION","enrollment":108},{"nctId":"NCT01340573","phase":"","title":"Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03-23","conditions":"Chronic Hepatitis C","enrollment":3},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT01440595","phase":"PHASE2","title":"Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-28","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT01180790","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2010-09","conditions":"Hepatitis C","enrollment":122},{"nctId":"NCT01678131","phase":"PHASE1","title":"Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-30","conditions":"Chronic Hepatitis C","enrollment":31},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":"Chronic Hepatitis C Virus Infection","enrollment":222},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT00910624","phase":"PHASE3","title":"Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-06-22","conditions":"Hepatitis C, Chronic","enrollment":168},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT01590225","phase":"PHASE3","title":"Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-28","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT00919633","phase":"PHASE2","title":"Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C","status":"COMPLETED","sponsor":"Medtronic Corporate Technologies and New Ventures","startDate":"2009-06","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01405937","phase":"PHASE3","title":"Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-08-29","conditions":"Hepatitis C, Chronic","enrollment":51},{"nctId":"NCT01370642","phase":"PHASE3","title":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":294},{"nctId":"NCT01405560","phase":"PHASE3","title":"Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-02","conditions":"Hepatitis C, Chronic","enrollment":42},{"nctId":"NCT02358044","phase":"PHASE3","title":"Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Hepatitis C","enrollment":257},{"nctId":"NCT01390844","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-21","conditions":"Hepatitis C, Chronic","enrollment":282},{"nctId":"NCT00689390","phase":"PHASE2, PHASE3","title":"Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-20","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":1954},{"nctId":"NCT01756079","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-06","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT02103439","phase":"PHASE3","title":"An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-06-06","conditions":"Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection","enrollment":140},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT02060058","phase":"PHASE3","title":"Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2013-11","conditions":"Hepatitis C, Chronic","enrollment":12},{"nctId":"NCT00803309","phase":"PHASE4","title":"Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients","status":"TERMINATED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":99},{"nctId":"NCT02099604","phase":"PHASE3","title":"Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-04","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133},{"nctId":"NCT00687219","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":102},{"nctId":"NCT00759109","phase":"PHASE3","title":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-03","conditions":"Carcinoma, Hepatocellular","enrollment":150},{"nctId":"NCT00705432","phase":"PHASE3","title":"Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":1472},{"nctId":"NCT00255034","phase":"PHASE4","title":"Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":146},{"nctId":"NCT00378599","phase":"PHASE3","title":"Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis","enrollment":125},{"nctId":"NCT00687544","phase":"PHASE4","title":"Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12","conditions":"Hepatitis C, Chronic, Hepacivirus, HIV Infections","enrollment":11},{"nctId":"NCT00255008","phase":"PHASE4","title":"Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00202839","phase":"PHASE4","title":"Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic","enrollment":160},{"nctId":"NCT00265395","phase":"PHASE3","title":"Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":1428},{"nctId":"NCT00686517","phase":"PHASE3","title":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-12","conditions":"Hepatitis C","enrollment":130},{"nctId":"NCT00302081","phase":"PHASE3","title":"Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-08","conditions":"Hepatitis C, Chronic","enrollment":696},{"nctId":"NCT00441584","phase":"PHASE3","title":"The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic","enrollment":117},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765},{"nctId":"NCT00104052","phase":"PHASE3","title":"Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-02","conditions":"Hepatitis C, Chronic","enrollment":107},{"nctId":"NCT00048724","phase":"PHASE3","title":"Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06","conditions":"Chronic Hepatitis C, Cirrhosis","enrollment":631},{"nctId":"NCT00081770","phase":"PHASE3","title":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-03","conditions":"Hepatitis C, Chronic","enrollment":4469},{"nctId":"NCT00049842","phase":"PHASE3","title":"Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10","conditions":"Chronic Hepatitis C, Liver Fibrosis","enrollment":540},{"nctId":"NCT00039871","phase":"PHASE3","title":"PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-05","conditions":"Hepatitis, Hepatitis C, Chronic, Fibrosis","enrollment":2333},{"nctId":"NCT00761735","phase":"PHASE3","title":"5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Hepatitis C, Chronic","enrollment":94},{"nctId":"NCT01447446","phase":"","title":"An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Hepatitis C, Chronic","enrollment":4442},{"nctId":"NCT00248339","phase":"PHASE3","title":"Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2002-05","conditions":"Hepatitis C","enrollment":150},{"nctId":"NCT01770223","phase":"PHASE4","title":"A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00811967","phase":"PHASE3","title":"Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-02","conditions":"Hepatitis C, Chronic, Liver Cirrhosis","enrollment":50},{"nctId":"NCT00277238","phase":"PHASE2","title":"CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02","conditions":"Hepatitis, Chronic Active","enrollment":113},{"nctId":"NCT00422838","phase":"","title":"Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2007-01","conditions":"Hepatitis C, Liver, Immunology","enrollment":20},{"nctId":"NCT01463956","phase":"PHASE2","title":"Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2012-01-06","conditions":"HCV Infection, Liver Cirrhosis, Experimental","enrollment":58},{"nctId":"NCT01280656","phase":"","title":"A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Hepatitis C, Chronic","enrollment":660},{"nctId":"NCT01838772","phase":"PHASE4","title":"HCV Treatment in HIV Co-Infected Patients in Asia","status":"COMPLETED","sponsor":"amfAR, The Foundation for AIDS Research","startDate":"2013-12","conditions":"Hepatitis C, HIV","enrollment":188},{"nctId":"NCT01066819","phase":"","title":"PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":1656},{"nctId":"NCT01701063","phase":"PHASE1, PHASE2","title":"An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Hepatitis C","enrollment":42},{"nctId":"NCT00087607","phase":"PHASE4","title":"Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Hepatitis C, Chronic","enrollment":385},{"nctId":"NCT00087568","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-01","conditions":"Hepatitis C, Chronic","enrollment":57},{"nctId":"NCT01066793","phase":"","title":"PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Hepatitis C, Chronic","enrollment":2343},{"nctId":"NCT02168361","phase":"PHASE4","title":"The SIM-SOF Trial for Hepatitis C","status":"COMPLETED","sponsor":"Center For Hepatitis C, Atlanta, GA","startDate":"2013-12","conditions":"Chronic Hepatitis C","enrollment":93},{"nctId":"NCT00087646","phase":"PHASE4","title":"REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-09","conditions":"Hepatitis C, Chronic","enrollment":948},{"nctId":"NCT00723645","phase":"","title":"Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04","conditions":"Hepatitis C, Chronic","enrollment":279},{"nctId":"NCT00709059","phase":"","title":"Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-12","conditions":"Hepatitis C, Chronic","enrollment":538},{"nctId":"NCT00723879","phase":"","title":"Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-10","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":115},{"nctId":"NCT00723892","phase":"","title":"Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":614},{"nctId":"NCT00724464","phase":"","title":"Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":332},{"nctId":"NCT01547312","phase":"PHASE1","title":"Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT02204475","phase":"PHASE3","title":"Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-11","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT00160251","phase":"PHASE2","title":"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Chronic Hepatitis C","enrollment":357},{"nctId":"NCT01016912","phase":"PHASE2","title":"Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis C Infection","enrollment":51},{"nctId":"NCT00727311","phase":"","title":"Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":2302},{"nctId":"NCT00726557","phase":"","title":"Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Hepatitis C, Chronic, Substance Abuse, Intravenous","enrollment":246},{"nctId":"NCT00704964","phase":"","title":"Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-05","conditions":"Hepatitis C, Chronic Hepatitis C","enrollment":746},{"nctId":"NCT00704522","phase":"","title":"Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":601},{"nctId":"NCT00725751","phase":"","title":"Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Hepatitis C, Chronic","enrollment":353},{"nctId":"NCT00723632","phase":"","title":"Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":901},{"nctId":"NCT00705666","phase":"","title":"Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Hepatitis C, Chronic, Hepacivirus","enrollment":789},{"nctId":"NCT00724373","phase":"","title":"Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11","conditions":"Hepatitis C, Chronic","enrollment":442},{"nctId":"NCT00724451","phase":"","title":"Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-07","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":1128},{"nctId":"NCT00725842","phase":"","title":"Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Hepatitis C, Hepatitis C, Chronic","enrollment":97},{"nctId":"NCT01641666","phase":"PHASE3","title":"Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05","conditions":"Chronic Hepatitis C","enrollment":""},{"nctId":"NCT01740089","phase":"PHASE2, PHASE3","title":"Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biocad","startDate":"2011-11","conditions":"Hepatitis, Hepatitis C","enrollment":150},{"nctId":"NCT00724893","phase":"","title":"Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":2430},{"nctId":"NCT01579474","phase":"PHASE3","title":"Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-04","conditions":"Hepatitis C","enrollment":131},{"nctId":"NCT00728494","phase":"","title":"Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Hepatitis C, Chronic, Hepatitis C","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PEGIntron plus ribavirin","genericName":"PEGIntron plus ribavirin","companyName":"Hepatitis Resource Network","companyId":"hepatitis-resource-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEGIntron (peginterferon alfa-2b) activates interferon signaling to suppress hepatitis C virus replication, while ribavirin inhibits viral RNA synthesis through multiple mechanisms. Used for Chronic hepatitis C virus infection (genotype-dependent).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}